Met Life Investment Management, LLC Arcus Biosciences, Inc. Transaction History

Met Life Investment Management, LLC

  • $18 Billion
  • Q4 2024

A detailed history of Met Life Investment Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 33,525 shares of RCUS stock, worth $439,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,525
Previous 31,004 8.13%
Holding current value
$439,177
Previous $474,000 5.27%
% of portfolio
0.0%
Previous 0.0%

Shares

42 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$14.28 - $18.44 $35,999 - $46,487
2,521 Added 8.13%
33,525 $499,000
Q2 2024

Aug 13, 2024
BUY
$14.59 - $18.48 $41,873 - $53,037
2,870 Added 10.2%
31,004 $472,000
Q1 2024

May 14, 2024
BUY
$14.83 - $20.18 $417,227 - $567,744
28,134 New
28,134 $531,000
Q3 2023

May 09, 2024
BUY
$17.62 - $23.54 $21,196 - $28,318
1,203 Added 4.47%
28,134 $505,000
Q2 2023

Apr 29, 2024
BUY
$16.97 - $22.03 $477,433 - $619,792
28,134 New
28,134 $571,000
Q2 2023

Aug 10, 2023
BUY
$16.97 - $22.03 $20,414 - $26,502
1,203 Added 4.47%
28,134 $571,000
Q1 2023

May 09, 2024
BUY
$15.96 - $23.15 $429,818 - $623,452
26,931 New
26,931 $491 Million
Q4 2022

May 10, 2024
BUY
$19.7 - $35.71 $9,456 - $17,140
480 Added 1.81%
26,931 $556,000
Q4 2022

Mar 22, 2023
BUY
$19.7 - $35.71 $9,456 - $17,140
480 Added 1.81%
26,931 $556,000
Q4 2022

Feb 15, 2023
BUY
$19.7 - $35.71 $9,456 - $17,140
480 Added 1.81%
26,931 $556,000
Q3 2022

Jun 14, 2023
SELL
$23.23 - $30.07 $11,150 - $14,433
-480 Reduced 1.78%
26,451 $691,000
Q2 2022

May 10, 2024
BUY
$17.23 - $37.73 $24,328 - $53,274
1,412 Added 5.64%
26,451 $670,000
Q2 2022

Jun 20, 2023
SELL
$17.23 - $37.73 $8,270 - $18,110
-480 Reduced 1.78%
26,451 $670,000
Q2 2022

Mar 22, 2023
BUY
$17.23 - $37.73 $24,328 - $53,274
1,412 Added 5.64%
26,451 $670,000
Q2 2022

Aug 11, 2022
BUY
$17.23 - $37.73 $24,328 - $53,274
1,412 Added 5.64%
26,451 $670,000
Q1 2022

May 10, 2024
BUY
$28.92 - $41.83 $724,127 - $1.05 Million
25,039 New
25,039 $790,000
Q1 2022

Jun 20, 2023
SELL
$28.92 - $41.83 $54,716 - $79,142
-1,892 Reduced 7.03%
25,039 $790,000
Q1 2022

Mar 22, 2023
BUY
$28.92 - $41.83 $263,952 - $381,782
9,127 Added 57.36%
25,039 $790,000
Q1 2022

May 12, 2022
BUY
$28.92 - $41.83 $263,952 - $381,782
9,127 Added 57.36%
25,039 $790,000
Q4 2021

Jun 21, 2023
SELL
$31.38 - $48.47 $345,776 - $534,090
-11,019 Reduced 40.92%
15,912 $643,000
Q3 2021

May 17, 2024
SELL
$26.93 - $37.68 $66,947 - $93,672
-2,486 Reduced 13.51%
15,912 $554,000
Q3 2021

Jun 21, 2023
SELL
$26.93 - $37.68 $296,741 - $415,195
-11,019 Reduced 40.92%
15,912 $554,000
Q3 2021

Mar 22, 2023
SELL
$26.93 - $37.68 $66,947 - $93,672
-2,486 Reduced 13.51%
15,912 $554,000
Q3 2021

Nov 15, 2021
SELL
$26.93 - $37.68 $66,947 - $93,672
-2,486 Reduced 13.51%
15,912 $555,000
Q2 2021

Jun 21, 2023
SELL
$22.75 - $35.77 $194,125 - $305,225
-8,533 Reduced 31.68%
18,398 $505,000
Q1 2021

May 17, 2024
SELL
$26.16 - $41.39 $254,693 - $402,973
-9,736 Reduced 34.61%
18,398 $516,000
Q1 2021

Jun 26, 2023
SELL
$26.16 - $41.39 $223,223 - $353,180
-8,533 Reduced 31.68%
18,398 $517 Million
Q4 2020

Jun 22, 2023
SELL
$17.0 - $32.36 $145,061 - $276,127
-8,533 Reduced 31.68%
18,398 $477,000
Q3 2020

May 24, 2024
BUY
$17.14 - $25.47 $47,186 - $70,118
2,753 Added 17.6%
18,398 $315 Million
Q3 2020

Jun 26, 2023
SELL
$17.14 - $25.47 $146,255 - $217,335
-8,533 Reduced 31.68%
18,398 $315,000
Q3 2020

Mar 22, 2023
BUY
$17.14 - $25.47 $47,186 - $70,118
2,753 Added 17.6%
18,398 $315,000
Q3 2020

Nov 13, 2020
BUY
$17.14 - $25.47 $47,186 - $70,118
2,753 Added 17.6%
18,398 $315,000
Q2 2020

May 24, 2024
SELL
$13.97 - $36.56 $174,471 - $456,597
-12,489 Reduced 44.39%
15,645 $387 Million
Q2 2020

Jun 26, 2023
SELL
$13.97 - $36.56 $157,665 - $412,616
-11,286 Reduced 41.91%
15,645 $387,000
Q1 2020

Jul 12, 2023
SELL
$8.78 - $19.28 $99,091 - $217,594
-11,286 Reduced 41.91%
15,645 $217,000
Q4 2019

Jul 12, 2023
SELL
$7.33 - $10.79 $82,726 - $121,775
-11,286 Reduced 41.91%
15,645 $158,000
Q3 2019

Jul 12, 2023
SELL
$6.44 - $10.18 $72,681 - $114,891
-11,286 Reduced 41.91%
15,645 $142,000
Q2 2019

Jul 12, 2023
SELL
$7.29 - $13.38 $82,274 - $151,006
-11,286 Reduced 41.91%
15,645 $124,000
Q1 2019

Jul 13, 2023
SELL
$8.95 - $12.49 $101,009 - $140,962
-11,286 Reduced 41.91%
15,645 $195,000
Q4 2018

Jul 13, 2023
SELL
$9.74 - $14.5 $109,925 - $163,647
-11,286 Reduced 41.91%
15,645 $168,000
Q4 2018

Mar 22, 2023
SELL
$9.74 - $14.5 $109,925 - $163,647
-11,286 Reduced 41.91%
15,645 $168,000
Q4 2018

Feb 14, 2019
BUY
$9.74 - $14.5 $152,382 - $226,852
15,645 New
15,645 $168,000

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.7M
Call Options Held
238K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $945M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email